Join to View Full Profile
5841 S Maryland AveChicago, IL 60637
Phone+1 888-824-0200
Fax+1 773-702-3163
Dr. Liao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Liao is an Assistant Professor of Medicine at the University of Chicago, the Medical Director of Hematology/Oncology clinic, the Interim Director of the Gastrointestinal Oncology Program, and the Co-Director of the Neuroendocrine Tumor Program. He is a medical oncologist and clinical investigator who treats and conducts clinical trials for biliary tract cancers, hepatocellular carcinoma, and gastrointestinal neuroendocrine tumors.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2014 - 2017
Rush University Medical CenterResidency, Internal Medicine, 2011 - 2014
Vanderbilt University School of MedicineClass of 2011
Certifications & Licensure
IN State Medical License 2023 - 2027
IL State Medical License Active through 2026
MO State Medical License 2014 - 2017
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Evaluating the role of postoperative long-acting somatostatin analog therapy in patients with metastatic neuroendocrine tumors undergoing surgical debulking.Theodoros Michelakos, Joseph Tobias, Sara Abou Azar, Blase Polite, J Michael Millis
Surgery. 2025-10-09 - Final Results from a First-in-Human Phase 1 Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 ...James J Harding, Do-Youn Oh, Teresa Macarulla Mercade, Lipika Goyal, Andreas Varkaris
Clinical Cancer Research. 2025-09-30 - Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: A Phase II Study.Sarbajit Mukherjee, Yu Fujiwara, Christos Fountzilas, Harsha Pattnaik, Sarah Chatley
Cancer Medicine. 2025-04-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
